Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?
10:56am, Tuesday, 30'th Jan 2024
The consensus price target hints at a 134.8% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick
09:46am, Wednesday, 10'th Jan 2024
Ocular Therapeutix (OCUL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
09:03am, Saturday, 23'rd Dec 2023
Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
08:00am, Wednesday, 08'th Nov 2023
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap
Ocular Therapeutix, Inc. (OCUL) Q3 2023 Earnings Call Transcript
10:32pm, Tuesday, 07'th Nov 2023
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President and CEO Rabia Ozden - CMO St
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
10:33pm, Sunday, 24'th Sep 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big phar
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
08:00am, Wednesday, 09'th Aug 2023
BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative ther
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
08:24pm, Monday, 07'th Aug 2023
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.28 per share a year ago.
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 01'st Jun 2023
BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative ther
Ocular Therapeutix, Inc. (OCUL) Q1 2023 Earnings Call Transcript
09:00pm, Monday, 08'th May 2023
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Execut
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
07:45pm, Monday, 08'th May 2023
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
08:00am, Monday, 08'th May 2023
BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
08:00am, Friday, 28'th Apr 2023
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative ther
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
08:00am, Monday, 24'th Apr 2023
BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
